// App-Quantinova.ai

Filters

Biomarkers











Conference Name











Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























1321 Abstracts

Analysis of circulating tumor DNA and clinical correlates in patients with esophageal, gastroesophageal junction and gastric adenocarcinoma.

Ryosuke Okamura - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Genotyping of circulating tumor DNA in biliary tract cancer reveals diagnostic and prognostic information.

Andreas Wolfgang Berger - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

TP53

Postradiation ctDNA status as a prognostic factor in locally advanced esophageal squamous cell carcinoma.

Ru Jia - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Association between mutation variant allele fractions (mVAFs) and response to immunotherapy (IO) in metastatic renal cell carcinoma (mRCC).

Nazli Dizman - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

Effects of molecular tumor board and different NGS panels implementation for the treatment of patients with cancer.

Christian Diego Rolfo - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Development and validation of ColoScape: A new colorectal cancer mutation detection assay.

Michael Joseph Powell - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Oncogenic mutation within the 3-C loop of EGFR/ERBB2/BRAF/MAP2K1.

Jie Gao - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

ERBB2 mutation profiling with next-generation sequencing (NGS) in solid tumors.

Fei Ma - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Circulating tumor DNA analysis for osimertinib resistance Chinese NSCLC patients.

Weiguang Gu - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Tagrisso

Circulating tumor DNA clone analysis to predict disease progression/indicates trastuzumab-resistant mechanism in advanced gastric cancer.

Yan Wang - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Trastuzumab

Applications of liquid biopsies as prognostic markers in patients (pts) with advanced ovarian cancer (AOC) on metronomic cyclophosphamide (MCy) with or without nintedanib (N) (Trans METRO-BIBF).

Marcia Hall - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

calcium/fluoride

Mutation tracking of circulating tumor DNA during neoadjuvant period predicts relapse in stage II-III breast cancer patients.

Po-Han Lin - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Cell-free circulating tumour DNA (ctDNA) in the management of patients (pts) with non-biopsiable (Bx) advanced non-small cell lung cancer (NSCLC).

MArina Kushnir - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Circulating tumor DNA (ctDNA) for genomic profiling of non-small cell lung cancer (NSCLC): Experience in a large community-based cancer center.

Giselle Alexandra Suero-Abreu - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

A CODAR-PCR assay using nucleic acids extracted from whole blood samples to provide superior sensitivity in EGFR T790M mutation detection and accurate prediction of osimertinib response in advanced NSCLC patients.

Qiong Zhao - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Tagrisso

Methylomes variation to predict exemestane resistance in advanced breast cancer.

Xiao-Ran Liu - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Exemestane

EFIRM liquid biopsy (eLB): Detection of ultra-short circulating tumor DNA (usctDNA) in plasma and saliva of non-small cell lung cancer (NSCLC) patients.

Feng Li - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Therapeutic response monitoring using digital PCR for patient-specific circulating tumor DNA identified by an esophageal squamous cell carcinoma-specific sequencing panel.

Takeshi Iwaya - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Docetaxel

SPANOM: A cost-effective method of detecting MSI in ctDNA.

Zhenghang Wang - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Fusion detection and longitudinal circulating tumor DNA (ctDNA) profiling in ALK+ non-small cell lung cancer (NSCLC) patients.

Aurelie Swalduz - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved